Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients

AUTOR(ES)

Mohr, John F.

FONTE

American Society for Microbiology

RESUMO

The pharmacokinetics of intravenous itraconazole (ITC) was studied in dialysis patients. Dialysis had no effect on the half-life and clearance of ITC or OH-ITC. However, dialysis allowed the clearance of hydroxypropyl-β-cyclodextrin (HP-β-CD). The area under the concentration-time curve from time zero to infinity (AUC0-∞) for HP-β-CD administered before dialysis was lower than the AUC0-∞ when it was administered after dialysis (P < 0.01). Administration of ITC intravenously just prior to hemodialysis appears to produce adequate systemic exposures of ITC and OH-ITC while allowing dialysis clearance of HP-β-CD. Studies of multiple administrations are warranted.

Documentos Relacionados

• Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.
• Pharmacokinetics of Tobramycin in Patients with Stable Renal Impairment, Patients Undergoing Peritoneal Dialysis, and Patients on Chronic Hemodialysis
• Itraconazole pharmacokinetics in patients with renal dysfunction.
• Pharmacokinetics and Safety of a 7-Day Administration of Intravenous Itraconazole followed by a 14-Day Administration of Itraconazole Oral Solution in Patients with Hematologic Malignancy
• Pharmacokinetics of Intravenous Amoxicillin in Pediatric Patients